The Shotlee Journal
Browse Shotlee articles about GLP-1 Medications.
Showing 9 / 934 GLP-1 Medications articles
While generics have revolutionized drug affordability, newer biologics like those used for weight loss and diabetes face unique challenges. A new study reveals how varying international regulations are slowing the adoption of affordable biosimilars, impacting patient access and costs.
Millions are experiencing transformative weight loss with GLP-1 agonists like Ozempic and Wegovy. However, many encounter plateaus. Groundbreaking research from the NIH is shedding light on why this happens within the brain's appetite control centers, potentially paving the way for more effective and personalized treatment plans.
While GLP-1 medications are celebrated for their effectiveness in managing type 2 diabetes and aiding weight loss, a growing concern is the potential for nutrient deficiencies. This article delves into the science behind this 'under-the-radar' side effect and what proactive steps you can take.
New research is exploring the surprising potential of GLP-1 receptor agonists, known for their role in diabetes and weight management, to also influence mental well-being. This article delves into the latest findings and what they mean for patients.
Eli Lilly's experimental drug retatrutide is showing unprecedented weight loss results, pushing the boundaries of what's possible. But with great power comes great responsibility, and doctors are urging caution.
The rapid adoption of GLP-1 agonists like Ozempic and Wegovy is forcing a profound realignment in the food and beverage industry. Initial hopes that users would eventually return to old habits have faded, replaced by a strategic pivot toward 'companion nutrition' tailored to the specific, evolving needs of individuals managing weight and metabolic health.
New-generation GLP-1 drugs like retatrutide promise unprecedented weight loss, but what are the implications for your body's composition and overall health? This article delves into the science, risks, and strategies for navigating rapid weight reduction.
South Africa's regulatory bodies are taking decisive action against the booming market for compounded GLP-1 weight-loss drugs, including versions of Ozempic and Mounjaro. This crackdown highlights significant safety concerns and potential risks to public health.
GLP-1 receptor agonists have revolutionized weight loss and diabetes management, but researchers are continuously seeking ways to enhance their delivery. This article delves into cutting-edge advancements, from nanocarriers to microneedles, aiming to make these powerful therapies more effective, tolerable, and convenient.
